P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL. (23rd June 2022)

• Record Type: Journal Article
• Authors: Mai, E. K.; Bertsch, U.; Fenk, R.; Tichy, D.; Besemer, B.; Dürig, J.; Schroers, R.; von Metzler, I.; Hänel, M.; Mann, C.; Asemissen, A. M.; Heilmeier, B.; Nievergall, E.; Huhn, S.; Kriegsmann, K.; Weinhold, N.; Luntz, S.; Holderrried, T. A. W.; Trautmann-Grill, K.; Gezer, D.; Klaiber-Hakimi, M.; Müller, M.; Khandanpour, C.; Knauf, W.; Scheid, C.; Munder, M.; Geer, T.; Riesenberg, H.; Thomalla, J.; Hoffmann, M.; Raab, M. S.; Salwender, H. J.; Weisel, K. C.; Goldschmidt, H.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 820
• Page End: 821
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000846588.94000.04
• Languages: English
• ISSNs: 2572-9241